化疗、养正桂苓汤联合盐酸安罗替尼治疗铂敏感复发性卵巢癌的临床研究

Application effect of Yangzheng Guiling decoction combined with anlotinib hydrochloride and chemotherapy in reversing platinum-sensitive recurrent ovarian cancer

目的观察化疗、养正桂苓汤联合盐酸安罗替尼治疗铂敏感复发性卵巢癌的临床价值。方法将78例铂敏感复发性卵巢癌患者按照随机数字表法分为2组,对照组39例予紫杉醇^(+)顺铂化疗,联合组39例在对照组治疗基础上予养正桂苓汤联合盐酸安罗替尼治疗,2组均治疗6周。比较2组治疗前后中医证候评分、Karnofsky评分(KPS)、糖类抗原125(CA125)表达、T淋巴细胞亚群(CD3^(+)、CD3^(+)CD4^(+)、CD3^(+)CD8^(+)、CD3^(+)CD4^(+)/CD3^(+)CD8^(+))表达,并统计毒副反应情况。结果2组治疗后中医证候各项评分及总分均较本组治疗前降低(P<0.05),且治疗组治疗后均低于对照组(P<0.05)。2组治疗后KPS评分均较本组治疗前升高(P<0.05),且治疗组治疗后高于对照组(P<0.05)。2组治疗后CA125水平均较本组治疗前降低(P<0.05),且治疗组治疗后低于对照组(P<0.05)。2组治疗后CD3^(+)CD4^(+)、CD3^(+)CD4^(+)/CD3^(+)CD8^(+)表达均较本组治疗前升高(P<0.05),联合组治疗后CD3^(+)CD8^(+)表达降低(P<0.05),联合组治疗后CD3^(+)CD4^(+)、CD3^(+)CD4^(+)/CD3^(+)CD8^(+)表达高于对照组(P<0.05),CD3^(+)CD8^(+)表达低于对照组(P<0.05)。联合组治疗后毒副反应发生情况低于对照组(P<0.05)。结论紫杉醇联合顺铂化疗与养正桂苓汤联合盐酸安罗替尼能有效降低铂敏感复发性卵巢癌患者的血清CA125表达,改善免疫功能,毒副反应低,安全性高。

Objective To explore the application value of Yangzheng Guiling decoction combined with anlotinib hydrochloride in reversing platinum-sensitive recurrent ovarian cancer.Methods Seventy-eight patients with platinum-sensitive recurrent ovarian cancer were randomly assigned to two groups according to the number table method.On the basis of paclitaxel^(+)cisplatin chemotherapy(the control group,n=39),the combined group(n=39)received Yangzheng Guiling Tang combined with arotinib hydrochloride treatment for 6 weeks.The efficacy of traditional Chinese medicine(TCM)syndrome,Karnofsky(KPS)score,carbohydrate antigen 125(CA125)and T lymphocyte subsets(CD3^(+),CD3^(+)CD4^(+),CD3^(+)CD8^(+),CD3^(+)CD4^(+)/CD3^(+)CD8^(+))were included as comparisons.The incidence of adverse reactions was recorded.Results After treatment,TCM syndromes scores and CA125 level in the two groups were lower than those before treatment(P<0.05),and which were lower in the treatment group than in the control group.(P<0.05).KPS scores in the two groups were higher than those before treatment(P<0.05),and the treatment group was higher than the control group(P<0.05).CD3^(+)CD4^(+)and CD3^(+)CD4^(+)/CD3^(+)CD8^(+)in the two groups were higher than those before treatment(P<0.05),and which were higher in the combined group than in the control group(P<0.05).CD3^(+)CD8^(+)in the combined group was decreased(P<0.05),and which was lower than in the control group(P<0.05).The incidence of adverse reactions in the combined group was lower than that in the control group(P<0.05).Conclusion For patients with platinum-sensitive recurrent ovarian cancer,the combination of the three can effectively reduce the expression of serum CA125,improve immune function,low toxicity and high safety.